In a phase I trial, Falchook et al. [97] demonstrated that sequential treatment with a combination of the nucleoside analogue azacytidine, the HDAC valproic acid and carboplatin decreased DR4 methylation, but there was no relationship with either tumor response or number of therapy cycles received. This evidence concerns the gene HDAC9 and neoplasm.